22:01 , Mar 15, 2019 |  BioCentury  |  Product Development

Broadening the PARP playing field

With its latest clinical win for Lynparza, AstraZeneca is leading the field in stretching the use of PARP inhibitors beyond tumors that carry BRCA mutations. The results highlight one piece of a broader strategy companies...
23:51 , Mar 14, 2019 |  BC Week In Review  |  Company News

GTx and Oncternal merging

GTx and Oncternal will merge to create a company focused on developing cancer therapies. Oncternal Therapeutics Inc. (San Diego, Calif.) will hold about 75% of the combined company, which will trade on NASDAQ under the...
17:27 , Mar 8, 2019 |  BC Week In Review  |  Clinical News

Darolutamide leads to metastasis-free survival of 40.4 months in non-metastatic CRPC

Bayer and Orion reported detailed data on Feb. 14 from the Phase III ARAMIS trial to treat non-metastatic castration-resistant prostate cancer showing that darolutamide led to metastasis-free survival, the primary endpoint, of 40.4 months vs....
22:14 , Mar 1, 2019 |  BioCentury  |  Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
19:49 , Feb 15, 2019 |  BC Week In Review  |  Clinical News

Xtandi reduces radiographic PFS by 61% in metastatic hormone-sensitive prostate cancer

Astellas Pharma Inc. (Tokyo:4503) and Pfizer Inc. (NYSE:PFE) reported that Xtandi enzalutamide plus androgen deprivation therapy (ADT) reduced the risk of radiographic progression or death, the primary endpoint, by 61% vs. ADT alone in the...
15:59 , Feb 6, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer In vitro and mouse studies identified a chromenecarbaldehyde-based IRE1 inhibitor that could help treat prostate cancer. Optimization and in vitro binding assays of a family of tool compound IRE1 inhibitors yielded a...
16:04 , Feb 5, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture and mouse studies identified an aryloxytetramethylcyclobutane-based degrader of androgen receptor that could help treat prostate cancer. Chemical synthesis and testing in three prostate cancer cells lines of analogs of a...
01:12 , Feb 1, 2019 |  BC Week In Review  |  Clinical News

J&J's Erleada meets in Phase III for castration-sensitive prostate cancer

Janssen Pharmaceuticals Inc. said a preplanned analysis by an IDMC showed that Erleada apalutamide met the dual primary endpoints in the Phase III TITAN trial to treat metastatic castration-sensitive prostate cancer (CSPC). The Johnson &...
18:38 , Jan 30, 2019 |  BC Extra  |  Clinical News

J&J's Erleada meets in Phase III for castration-sensitive prostate cancer

Janssen Pharmaceuticals Inc. said a preplanned analysis by an IDMC showed that Erleada apalutamide met the dual primary endpoints in the Phase III TITAN trial to treat metastatic castration-sensitive prostate cancer (CSPC). The Johnson &...
13:10 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture and mouse studies suggest inhibiting Hsp70 could help treat prostate cancer resistant to Xtandi enzalutamide and/or Zytiga abiraterone acetate. In human prostate cancer cell lines, high Hsp70 levels were associated...